Johnson & Johnson (JNJ) had a strong 2017 both on and off the stock market. The company stock maintained an upward trend throughout the year. Johnson & Johnson also won the FDA approval for first in class IL inhibitor treatment Tremfya for Plaque Psoriasis.
Earlier last year, Johnson & Johnson scored a big win as its Tremfya was approved by the FDA for treating moderate to severe Plaque Psoriasis in adult patients. With this approval, Tremfya is currently the only approved treatment in the market which is an only IL-23 inhibitor. The drug produced impressive results in three different trials, Voyage 1, Voyage 2 and Navigate, in its Phase 3 studies. These trials had close to 2,000 participants and showed significant improvement in the patients’ condition. The study also tested the drug against AbbVie’s Humira, which is widely perceived to be the benchmark drug for the condition. Tremfya reported 7 out of 10 patients achieving 90 percent improvement in their skin condition while in the case of Humira, only 4 out 10 patients reported same level of efficiency. The strong study results show that the drug is likely to get positive response in the market.